Page 67 - ITPS-7-3

INNOSC Theranostics and
Pharmacological Sciences Designing miRNA ONTs for cardiometabolic pandemics

studies. Biochem Pharmacol. 2021;189:114432. the wnt-responsive transcription factor Tcf7. Diabetes.
2015;64(11):3659-3669.
doi: 10.1016/j.bcp.2021.114432
doi: 10.2337/db14-1924
47. Ambros V. The functions of animal microRNAs. Nature.
2004;431(7006):350-355. 59. Hu Y, Liu HX, Jena PK, Sheng L, Ali MR, Wan YY. miR-22
inhibition reduces hepatic steatosis via FGF21 and FGFR1
doi: 10.1038/nature02871
induction. JHEP Rep. 2020;2(2):100093.
48. Kariuki D, Asam K, Aouizerat BE, Lewis KA, Florez JC,
Flowers E. Review of databases for experimentally validated doi: 10.1016/j.jhepr.2020.100093
human microRNA-mRNA interactions. Database (Oxford). 60. Castano C, Novials A, Parrizas M. Exosomes from short-
2023;2023:baad014. term high-fat or high-sucrose fed mice induce hepatic
steatosis through different pathways. Cells. 2022;12(1):169.
doi: 10.1093/database/baad014
doi: 10.3390/cells12010169
49. Alles J, Fehlmann T, Fischer U, et al. An estimate of the
total number of true human miRNAs. Nucleic Acids Res. 61. Panella R, Petri A, Desai BN, et al. MicroRNA-22 is a key
2019;47(7):3353-3364. regulator of lipid and metabolic homeostasis. Int J Mol Sci.
2023;24(16):12870.
doi: 10.1093/nar/gkz097
doi: 10.3390/ijms241612870
50. Hammond SM. An overview of microRNAs. Adv Drug Deliv
Rev. 2015;87:3-14. 62. Bennett CF, Baker BF, Pham N, Swayze E, Geary RS.
Pharmacology of antisense drugs. Annu Rev Pharmacol
doi: 10.1016/j.addr.2015.05.001
Toxicol. 2017;57:81-105.
51. Mohr AM, Mott JL. Overview of microRNA biology. Semin
Liver Dis. 2015;35(1):3-11. doi: 10.1146/annurev-pharmtox-010716-104846
63. Crooke ST, Baker BF, Crooke RM, Liang XH. Antisense
doi: 10.1055/s-0034-1397344
technology: An overview and prospectus. Nat Rev Drug
52. Hagedorn PH, Hansen BR, Koch T, Lindow M. Managing Discov. 2021;20:427-453.
the sequence-specificity of antisense oligonucleotides in doi: 10.1038/s41573-021-00162-z
drug discovery. Nucleic Acids Res. 2017;45(5):2262-2282.
64. Crooke ST, Liang XH, Baker BF, Crooke RM. Antisense
doi: 10.1093/nar/gkx056
technology: A review. J Biol Chem. 2021;296:100416.
53. Thibonnier M, Esau C. Metabolic benefits of Microrna-22
inhibition. Nucleic Acid Ther. 2020;30(2):104-116. doi: 10.1016/j.jbc.2021.100416
65. Goyenvalle A, Jimenez-Mallebrera C, van Roon W,
doi: 10.1089/nat.2019.0820
et al. Considerations in the preclinical assessment of the
54. Thibonnier M, Esau C, Ghosh S, Wargent E, Stocker C. safety of antisense oligonucleotides. Nucleic Acid Ther.
Metabolic and energetic benefits of microRNA-22 inhibition. 2023;33(1):1-16.
BMJ Open Diabetes Res Care. 2020;8(1):e001478.
doi: 10.1089/nat.2022.0061
doi: 10.1136/bmjdrc-2020-001478
66. Nielsen PE. Sequence-selective DNA recognition by
55. Keller A, Groger L, Tschernig T, et al. miRNATissueAtlas2: synthetic ligands. Bioconjug Chem. 1991;2(1):1-12.
An update to the human miRNA tissue atlas. Nucleic Acids doi: 10.1021/bc00007a001
Res. 2022;50(D1):D211-D221.
67. Nielsen PE, Egholm M, Berg RH, Buchardt O. Sequence-
doi: 10.1093/nar/gkab808
selective recognition of DNA by strand displacement
56. Thibonnier M, Ghosh S. Strategy for pre-clinical development with a thymine-substituted polyamide. Science.
of active targeting MicroRNA oligonucleotide therapeutics 1991;254(5037):1497-1500.
for unmet medical needs. Int J Mol Sci. 2023;24(8):7126.
doi: 10.1126/science.1962210
doi: 10.3390/ijms24087126
68. Pradeep SP, Malik S, Slack FJ, Bahal R. Unlocking the
57. Yang Z, Qin W, Huo J, Zhuo Q, Wang J, Wang L. MiR-22 potential of chemically modified peptide nucleic acids for
modulates the expression of lipogenesis-related genes RNA-based therapeutics. RNA. 2023;29(4):434-445.
and promotes hepatic steatosis in vitro. FEBS Open Bio. doi: 10.1261/rna.079498.122
2021;11(1):322-332.
69. Suparpprom C, Vilaivan T. Perspectives on conformationally
doi: 10.1002/2211-5463.13026
constrained peptide nucleic acid (PNA): Insights into the
58. Kaur K, Vig S, Srivastava R, et al. Elevated hepatic miR- structural design, properties and applications. RSC Chem
22-3p expression impairs gluconeogenesis by silencing Biol. 2022;3(6):648-697.

Volume 7 Issue 3 (2024) 14 doi: 10.36922/itps.3025